Ira Zackon, MD
Hematology & Oncology · Albany, NYNPI 1578550414
Payments from drug & device makers
Across 137 payments — averaging $1132.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$74K
- Merck$28K
- Epizyme, Inc.$21K
- Takeda Pharmaceuticals U.S.A., Inc.$15K
- Incyte Corporation$15K
- Morphosys, US Inc.$963
- plus $1K from 12 others
Across 1 payment — averaging $1188.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1K
What the payments were for
- Consulting fees$9631%
- Speaking & faculty fees$116,58092%
- Travel & lodging$6,7635%
- Food & beverage$2,8672%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 59 | $74,183 |
| Merck | 33 | $27,944 |
| Epizyme, Inc. | 5 | $20,500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $15,208 |
| Incyte Corporation | 13 | $14,922 |
| Morphosys, US Inc. | 1 | $963 |
| GE HealthCare | 2 | $808 |
| Genentech USA, Inc. | 2 | $143 |
| Seagen Inc. | 1 | $124 |
| Coherus Oncology, Inc. | 1 | $92 |
| Johnson & Johnson | 1 | $92 |
| Daiichi Sankyo Inc. | 1 | $67 |
| Pfizer | 2 | $40 |
| Sanofi | 1 | $28 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| AstraZeneca | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,183 in reported general payments places this provider in the 75th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 21 | $253,405 |
| Imatinib Mesylate | 20 | $38,723 |
| Acyclovir | 35 | $441 |
| Warfarin Sodium | 40 | $210 |
| Dexamethasone | 14 | $73 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Albany
- Makenzi EvangelistAlbany$5.9M
- Rahul RavillaAlbany$2.9M
- Vicky MakkerNew York$27.1M
- Alison MoskowitzNew York$22.7M
- Ajai ChariNew York$22.4M
- Yelena JanjigianNew York$16.9M
- Alexander LesokhinNew York$11.9M
- John MascarenhasNew York$11.8M
- Maria PalombaNew York$11.6M
- Richard ZunigaBabylon$10.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.